Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YQ23 in Critical Limb Ischaemia
NCT04792008Phase 2Terminated
- Sponsor
- New Beta Innovation
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of YQ23 in critical limb ischemia (CLI), sponsored by New Beta Innovation. Started Mar 2021; status: terminated.
02
Drugs
YQ23
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT04792008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792008.